Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Buy" by Brokerages

Key Points

• Centessa Pharmaceuticals PLC (NASDAQ:CNTA) has received a consensus rating of "Buy" from ten analysts, with an average 12-month target price of $32.38.
• Insider trading revealed that CTO Tia L. Bush sold 35,000 shares for $840,000, representing a 22.36% decrease in their position in the company.
• As of now, approximately 82.01% of Centessa Pharmaceuticals' stock is owned by hedge funds and institutional investors, reflecting strong interest from major financial players.

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) have been given a consensus recommendation of "Buy" by the ten ratings firms that are currently covering the firm, MarketBeat reports. Nine analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $32.3750.

A number of brokerages have recently weighed in on CNTA. Wall Street Zen lowered shares of Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Chardan Capital restated a "buy" rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a report on Friday, August 29th. They issued an "outperform" rating and a $40.00 price objective on the stock. Truist Financial began coverage on shares of Centessa Pharmaceuticals in a report on Monday, July 21st. They issued a "buy" rating and a $30.00 price objective on the stock. Finally, Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, September 3rd.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock opened at $23.26 on Monday. The firm has a market cap of $3.11 billion, a PE ratio of -12.99 and a beta of 1.47. Centessa Pharmaceuticals has a 52-week low of $9.60 and a 52-week high of $24.13. The company has a quick ratio of 10.12, a current ratio of 10.11 and a debt-to-equity ratio of 0.32. The company's 50 day moving average is $18.34 and its two-hundred day moving average is $15.08.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). On average, research analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Activity

In other news, CTO Tia L. Bush sold 35,000 shares of the firm's stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $24.00, for a total value of $840,000.00. Following the sale, the chief technology officer directly owned 121,503 shares in the company, valued at approximately $2,916,072. This trade represents a 22.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction on Monday, September 15th. The shares were sold at an average price of $21.85, for a total transaction of $131,100.00. Following the completion of the transaction, the general counsel directly owned 105,386 shares in the company, valued at $2,302,684.10. This trade represents a 5.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 205,286 shares of company stock valued at $3,993,345 over the last quarter. Company insiders own 7.09% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC grew its position in shares of Centessa Pharmaceuticals by 1,509.6% in the 1st quarter. GAMMA Investing LLC now owns 61,762 shares of the company's stock valued at $888,000 after buying an additional 57,925 shares during the last quarter. Cutter Capital Management LP grew its position in shares of Centessa Pharmaceuticals by 184.3% in the 1st quarter. Cutter Capital Management LP now owns 418,127 shares of the company's stock valued at $6,013,000 after buying an additional 271,051 shares during the last quarter. Cerity Partners LLC purchased a new position in shares of Centessa Pharmaceuticals in the 1st quarter valued at $471,000. American Century Companies Inc. grew its position in shares of Centessa Pharmaceuticals by 1.2% in the 1st quarter. American Century Companies Inc. now owns 1,092,754 shares of the company's stock valued at $15,714,000 after buying an additional 13,046 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at $320,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.